dc.contributor.advisor | Giuliano, Elizabeth A. | eng |
dc.contributor.author | Bosiack, Ann P. | eng |
dc.date.issued | 2012 | eng |
dc.date.submitted | 2012 Fall | eng |
dc.description | Title from PDF of title page (University of Missouri--Columbia, viewed on March 20, 2013). | eng |
dc.description | The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file; a non-technical general description, or public abstract, appears in the public.pdf file. | eng |
dc.description | Thesis advisor: Dr. Elizabeth A. Giuliano | eng |
dc.description | Includes bibliographical references. | eng |
dc.description | M.S. University of Missouri-Columbia 2012. | eng |
dc.description | "December 2012" | eng |
dc.description.abstract | [ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Canine corneal fibrosis is a significant clinical problem in veterinary ophthalmology. Corneal wound healing following injury or infection often results in corneal fibrosis. The transformation of quiescent keratocytes to corneal myofibroblasts has been identified as the primary event in corneal wound healing that is responsible for fibrosis. Transforming growth factor beta (TGF[beta]) is a cytokine that plays a critical role in facilitating the cellular turnover of keratocytes to corneal myofibroblasts. It has been shown that inhibition of corneal myofibroblast formation reduces corneal fibrosis. Therefore, utilizing pharmacologic agents or gene therapy to modulate TGF[beta] function may be a useful strategy to prevent the development of corneal fibrosis. The aims of the first study were (1) to determine the efficacy of adeno-associated vector serotype 5 (AAV5) for delivering gene therapy to canine corneal fibroblasts (CCFs) and myofibroblasts (CCMs) using enhanced green fluorescent protein (GFP) marker gene and (2) evaluate the cytotoxicity of AAV5 to CCFs and CCMs using an in vitro model. Study results supported the finding that tested AAV5 is an effective and safe vector for canine corneal gene therapy in this in vitro model. In vivo studies are warranted. Study aims of the second study were to evaluate the safety and efficacy of the FDA-approved drug vorinostat (suberoylanilide hydroxamic acid) in the treatment of canine corneal fibrosis using an in-vitro model. Study results showed that vorinostat safely and effectively inhibits TGF[beta]1-induced myofibroblast proliferation in the canine cornea in vitro. | eng |
dc.format.extent | vi, 63 pages | eng |
dc.identifier.uri | http://hdl.handle.net/10355/33465 | |
dc.language | English | eng |
dc.publisher | University of Missouri--Columbia | eng |
dc.relation.ispartofcommunity | University of Missouri--Columbia. Graduate School. Theses and Dissertations | eng |
dc.rights | Access to files is limited to the University of Missouri--Columbia. | eng |
dc.subject | canine corneal fibrosis | eng |
dc.subject | keratocytes | eng |
dc.subject | myofibroblasts | eng |
dc.subject | gene therapy | eng |
dc.subject | vorinostat | eng |
dc.title | New strategies in canine corneal wound healing for the veterinary ophthalmic patient | eng |
dc.type | Thesis | eng |
thesis.degree.discipline | Veterinary biomedical sciences (MU) | eng |
thesis.degree.grantor | University of Missouri--Columbia | eng |
thesis.degree.level | Masters | eng |
thesis.degree.name | M.S. | eng |